Buy Capnat

Capnat

What is Capnat?

Capnat is a brand-name oncology medication that contains the active ingredient capecitabine. Capecitabine is a chemotherapy pro-drug that is converted in the body to 5-fluorouracil (5-FU), a drug that interferes with the growth of cancer cells. Capnat is supplied as 500 mg oral pills and is prescribed by oncologists for use in combination with other cancer therapies. In the United Kingdom it is a prescription-only medicine (Rx) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

How Capnat Works in the Body

Capecitabine is taken by mouth and absorbed through the gastrointestinal tract. Once in the bloodstream it travels to tissues that have high levels of the enzyme thymidine phosphorylase, an enzyme that is often elevated in tumour cells. Within these cells, capecitabine is metabolised in three steps:

1. Conversion to 5′-deoxy-5-fluorocytidine (5′-dFC) by the enzyme carboxylesterase.
2. Conversion to 5′-deoxy-5-fluorouridine (5′-dFUrd) by cytidine deaminase.
3. Final conversion to 5-fluorouracil (5-FU) by thymidine phosphorylase.

The resulting 5-FU then disrupts the synthesis of DNA and RNA, preventing cancer cells from dividing and leading to cell death. Because the final activation step occurs preferentially in tumour tissue, capecitabine provides a degree of tumour-selective chemotherapy compared with direct 5-FU infusion.

Conditions Treated by Capnat

Capecitabine is approved in the UK for the following indications:

• Metastatic colorectal cancer (in combination with oxaliplatin or as monotherapy after failure of other regimens)
• Adjuvant treatment of stage III colon cancer (following surgical resection)
• Metastatic breast cancer (in combination with docetaxel or as a single agent after prior chemotherapy)

These uses are supported by the MHRA and are reflected in the product’s Summary of Product Characteristics (SPC). The medication is intended for adult patients whose cancer type matches one of the approved indications and who are under the care of a specialist oncology team.

Patient Suitability and Contraindications

Who Should Use Capnat?

Capnat is suited for adult patients with the above-listed cancers who have adequate organ function (liver, kidney, bone marrow) and for whom the treating oncologist determines that the benefits of therapy outweigh the risks.

Absolute Contraindications

• Known hypersensitivity to capecitabine or any of the excipients in the pill.
• Severe renal impairment (creatinine clearance < 30 mL/min) unless dose-adjusted by a specialist.
• Pregnant or breastfeeding women (capecitabine is classified as pregnancy category D due to fetal risk).

Relative Contraindications

• Moderate hepatic dysfunction (bilirubin > 1.5 × upper limit of normal).
• Pre-existing cardiac disease, as rare cardiac toxicity has been reported.
• Concurrent use of fluoropyrimidine-based chemotherapy agents without appropriate dose adjustments.

Special Populations

• Pregnancy/Lactation: Capecitabine can cause fetal harm; effective contraception is required during treatment and for at least three months after the final dose. Breastfeeding is contraindicated.
• Elderly Patients: Age alone is not a contraindication, but older adults may require dose reductions based on renal function and overall performance status.
• Renal or Hepatic Impairment: Dose modification is guided by laboratory results and clinical judgment.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Diarrhoea - often mild to moderate; maintain hydration and report severe or persistent episodes.
• Nausea and vomiting - may be mitigated with anti-emetic medication prescribed by the oncologist.
• Hand-foot syndrome (palmar-plantar erythrodysesthesia) - redness, swelling, or tenderness of the palms and soles; dose interruptions can help.
• Fatigue - common during chemotherapy cycles; balance rest with gentle activity as tolerated.

Serious Adverse Events

• Neutropenia or severe lymphopenia - increases infection risk; regular blood counts are required.
• Cardiac toxicity - rare cases of chest pain, arrhythmia, or myocardial ischaemia have been reported.
• Severe allergic reactions - rash, angioedema, or anaphylaxis require immediate medical attention.
• Severe diarrhoea leading to dehydration - may necessitate hospitalisation.

Drug Interactions

• Warfarin: Capecitabine can enhance anticoagulant effects; INR monitoring is advised.
• CYP2C9 inhibitors (e.g., fluconazole, amiodarone): May increase capecitabine plasma concentrations; dose adjustment may be needed.
• Other fluoropyrimidines: Concurrent use can amplify toxicity; combination therapy should be managed by an oncology specialist.
• Herbal products (e.g., St. John’s Wort): Potential for enzyme induction; patients should disclose all supplements.

Food and Lifestyle Interactions

• Food: Capecitabine tablets are usually taken within 30 minutes after a meal to improve absorption and reduce gastrointestinal upset.
• Alcohol: Moderate consumption is generally permissible, but excessive intake may exacerbate liver toxicity.
• Sun exposure: Hand-foot syndrome can be worsened by heat; patients are advised to protect their hands and feet from intense sunlight and hot environments.

Note: Always inform the oncology team of all prescribed medicines, over-the-counter products, herbal supplements, and lifestyle factors before starting Capnat.

How to Take Capnat

• Formulation: Capnat is supplied as a 500 mg oral pill. Swallow the tablet whole with a glass of water; do not crush, chew, or split unless instructed otherwise.
• Typical Regimen (general guidance): Many oncologists prescribe capecitabine in a 14-days-on, 7-days-off cycle, with the total daily dose calculated based on body surface area (BSA). The exact dose (often ranging from 1250 mg/m² to 2000 mg/m² per day) is split into two divided doses taken approximately 12 hours apart after meals.
• Individualisation: The precise dosing schedule, number of cycles, and any dose reductions are determined by the treating oncologist after evaluating laboratory results and treatment response.
• Missed Dose: If a dose is missed, take it as soon as remembered provided it is at least 8 hours before the next scheduled dose. Do not double the following dose.
• Overdose: Symptoms may include severe nausea, vomiting, diarrhoea, abdominal pain, and profound fatigue. Seek emergency medical care; supportive measures and, if needed, hospitalization are standard.
• Discontinuation: Capnan may be stopped or tapered based on treatment response, toxicity, or completion of the prescribed course. Never discontinue abruptly without consulting the oncology team.

Monitoring and Follow-Up

• Blood counts: Complete blood count (CBC) prior to each treatment cycle and weekly during the first two weeks of a cycle.
• Renal function: Serum creatinine and estimated glomerular filtration rate (eGFR) should be checked before initiating therapy and regularly thereafter.
• Liver enzymes: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) monitoring is recommended.
• Cardiac assessment: Baseline ECG may be performed in patients with known cardiac disease; repeat if symptoms arise.
• Clinical review: Patients should report any new or worsening side effects promptly. Routine imaging (CT, MRI) may be scheduled to assess tumour response according to the oncology protocol.

Storage and Handling

• Temperature: Store Capnat pills at 20-25 °C (68-77 °F). Protect from excessive heat, moisture, and direct sunlight.
• Container: Keep the medication in its original blister pack or bottle, tightly closed.
• Disposal: Unused or expired pills should be returned to a pharmacy-based medicine-take-back program or disposed of according to local NHS guidelines for hazardous waste.
• Child safety: Ensure the medication is kept out of reach of children and pets.

Medication-Specific Glossary

Prodrug

An inactive compound that is metabolised in the body to produce an active drug; capecitabine is a prodrug of 5-fluorouracil.

Hand-Foot Syndrome

A dermatologic toxicity characterised by redness, swelling, and pain on the palms and soles, commonly associated with capecitabine therapy.

Body Surface Area (BSA)

A calculated value (m²) based on height and weight used to determine appropriate chemotherapy dosing.

Thymidine Phosphorylase

An enzyme enriched in many tumour cells that converts capecitabine’s intermediate metabolites into the active chemotherapy agent 5-FU.

Medical Disclaimer

This article provides educational information about Capnat and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.